Y
Yasuo Suzuki
Researcher at Toho University
Publications - 198
Citations - 6447
Yasuo Suzuki is an academic researcher from Toho University. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 36, co-authored 193 publications receiving 5169 citations. Previous affiliations of Yasuo Suzuki include Chiba University.
Papers
More filters
Journal ArticleDOI
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka,Taku Kobayashi,Fumiaki Ueno,Toshiyuki Matsui,Fumihito Hirai,Nagamu Inoue,Jun Kato,Kenji Kobayashi,Kiyonori Kobayashi,Kazutaka Koganei,Reiko Kunisaki,Satoshi Motoya,Masakazu Nagahori,Hiroshi Nakase,Fumio Omata,Masayuki Saruta,Toshiaki Watanabe,Toshiaki Tanaka,Takanori Kanai,Yoshinori Noguchi,Ken Ichi Takahashi,Kenji Watanabe,Toshifumi Hibi,Yasuo Suzuki,Mamoru Watanabe,Kentaro Sugano,Tooru Shimosegawa +26 more
TL;DR: This English version was produced and edited based on the existing updated guidelines for ulcerative colitis and Crohn’s disease in Japanese, developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation system.
Journal ArticleDOI
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Haruhiko Ogata,Toshiyuki Matsui,Makoto Nakamura,Mitsuo Iida,Masakazu Takazoe,Yasuo Suzuki,Toshifumi Hibi +6 more
TL;DR: In this article, the authors demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory active ulcerative colitis (UC) patients.
Journal Article
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Commentary
Klaus Herrlinger,Klaus Fellermann,Eduard F. Stange,Haruhiko Ogata,Toshiyuki Matsui,M. Nakamura,Mitsuo Iida,Masakazu Takazoe,Yasuo Suzuki,Toshifumi Hibi +9 more
TL;DR: The findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC and the optimal target range appears to be 10–15 ng/ml in terms of efficacy with two week therapy.
Journal ArticleDOI
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study.
Takashi Shimoyama,Koji Sawada,Nobuo Hiwatashi,Toshio Sawada,Kei Matsueda,Akihiro Munakata,Hitoshi Asakura,Takao Tanaka,Reiji Kasukawa,Ken Kimura,Yasuo Suzuki,Yukio Nagamachi,Tetsuichiro Muto,Hirokazu Nagawa,Bunei Iizuka,Shozo Baba,Masaru Nasu,Tatsuji Kataoka,Nobuhito Kashiwagi,Abby R. Saniabadi +19 more
TL;DR: Based on the results, it is believed that in patients with active severe UC, patients who are refractory to conventional drugs, granulocyte and monocyte adsorption apheresis is a useful adjunct to conventional therapy.
Journal ArticleDOI
Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: A prospective, randomized trial
Takayuki Matsumoto,Satoshi Motoya,Kenji Watanabe,Tadakazu Hisamatsu,Hiroshi Nakase,Naoki Yoshimura,Tetsuya Ishida,Shingo Kato,T. Nakagawa,Motohiro Esaki,Masakazu Nagahori,Toshiyuki Matsui,Yuji Naito,Takanori Kanai,Yasuo Suzuki,Masanori Nojima,Mamoru Watanabe,Toshifumi Hibi +17 more
TL;DR: The clinical efficacy of a combination of adalimumab and azathioprine at WWeek 26 did not differ from that of ad alimumab monotherapy in patients with active Crohn's disease naïve to both medications.